OAKLAND PARK, FL / ACCESS Newswire / August 24, 2025 / EndoUVTech, a medical device innovator pioneering UV laser technology for treating blood clots in the brain, today announced a strategic partnership with CeramOptec, a global leader in specialty optical fibers for medical applications.

The collaboration marks another milestone in EndoUVTech's breakthrough treatment for stroke. The company's proprietary system uses a UV laser, delivered via a custom fiber optic cable and balloon catheter combination, to safely dissolve residual blood clots in the brain that remain after a mechanical thrombectomy.

"This partnership with CeramOptec has been critical to our commercialization path," said Chip Van Vurst, CEO of EndoUVTech. "Their ability to produce our highly specialized fiber at scale - one capable of delivering precise UV energy to cerebral vessels - is vital to bringing our technology to market."

CeramOptec's advanced manufacturing capabilities play a pivotal role in ensuring the reliability and performance of the UV system. The custom fiber, thinner than an human hair, enables EndoUVTech's device to trigger a natural photo chemical reaction that reaches otherwise inaccessible distal clots, achieving more complete revascularization and reducing the risk of long-term disability in stroke survivors.

"Our team is proud to support EndoUVTech in with this potentially life-saving technology," said Julien Demange, Head of Medical Applications at CeramOptec. "This partnership exemplifies how our high-performance optical fibers can help redefine what's possible in neurovascular care."

Unlike existing treatments that focus on large vessel occlusions, EndoUVTech's add on solution addresses a persistent clinical gap - residual clots that can cause secondary strokes, complications, or prevent full recovery. The system is used in conjunction with current methods and offers controlled arterial dilation while reducing vessel trauma that is common during current procedures, further enhancing patient outcomes.

EndoUVTech is on track to submit its lead device to the U.S. Food and Drug Administration (FDA) in Q4 2025 - a major step toward addressing unmet needs in both vascular and neurovascular stroke care.

About Endo UV Tech, Inc.

EndoUVtech is a medical device company headquartered in Oakland Park, Florida, dedicated to developing advanced technologies that improve outcomes for patients suffering from ischemic stroke (blood clots in the brain) and other cardiovascular conditions. Founded by a team of medical industry experts and scientists, the company focuses on UV-based devices that aim to reduce side effects and enhance recovery for stroke patients.

The company's flagship product, the "EndoSmartUV" Laser system, is designed to minimize tissue damage, improve clot removal during endovascular procedures, and dissolve downstream platelet clots that cause stroke side effects.

For more information, visit: www.endouvtech.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding potential product performance, anticipated regulatory approvals, and future market opportunities for EndoUVtech and its manufacturing partner. These statements are based on current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially from those projected.

Such risks and uncertainties include, but are not limited to, the timing and success of regulatory submissions and approvals, market acceptance of new products, manufacturing readiness, competition, intellectual property protection, and other factors. Endo UV Tech, Inc. undertakes no obligation to update forward-looking statements because of new information, future events, or otherwise, except as required by law.

Media Contact:

Lisa Goddard, Media Relations
Phone: (514) 817-5884
Email: lisa@EndoUVtech.com

Investor Inquiries:
Vincent Iantomasi, Investor Relations
Phone: (514) 947-4966
Email: vincent@EndoUVtech.com

SOURCE: EndoUVtech